Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study

Background The addition of a programmed death-ligand 1 (PD-L1) inhibitor, either atezolizumab or durvalumab, to platinum-etoposide prolonged survival in a limited subset of patients with extensive-stage small-cell lung cancer (ES-SCLC). Preclinical studies demonstrated synergistic antitumor activity...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcello Tiseo, Corrado Ficorella, Andrea Ardizzoni, Carlo Genova, Francesca Mazzoni, Giuseppe Lamberti, Luca Boni, Ida Colantonio, Alessandro Leonetti, Saverio Cinieri, Andrea Bonetti, Michele Tognetto, Federica Bertolini, Alessandro Follador, Elisa Andrini, Antonio Frassoldati, Francesco Gelsomino, Giulia Pasello, Karim Rihawi, Ferdinando Riccardi, Donatella Giardina, Matteo Brighenti
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e010694.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e010694.full

Similar Items